TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66^th ASH Annual Meeting and Exposition

IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01

Read more at globenewswire.com